Available corrector drugs are unable to effectively rescue the folding defects of CFTR-Δ F508 (or CFTR-F508del), the most common disease-causing mutation of the cystic fibrosis transmembrane conductance regulator, a plasma membrane (PM) anion channel, and thus to substantially ameliorate clinical phenotypes of cystic fibrosis (CF). To overcome the corrector efficacy ceiling, here we show that compounds targeting distinct structural defects of CFTR can synergistically rescue mutant expression and function at the PM. High-throughput cell-based screens and mechanistic analysis identified three small-molecule series that target defects at nucleotide-binding domain (NBD1), NBD2 and their membrane-spanning domain (MSD) interfaces. Although individually these compounds marginally improve Δ F508-CFTR folding efficiency, function and stability, their combinations lead to ~50-100% of wild-type-level correction in immortalized and primary human airway epithelia and in mouse nasal epithelia. Likewise, corrector combinations were effective against rare missense mutations in various CFTR domains, probably acting via structural allostery, suggesting a mechanistic framework for their broad application.
M ore than 2,000 mutations in the cystic fibrosis (CF)-causing gene, encoding the CF transmembrane conductance regulator (CFTR or ABCC7), have been identified (Cystic Fibrosis Mutation Database; http://www.genet.sickkids.on.ca/app). Most of these mutations manifest in loss of function of CFTR anion channel activity through complex cellular mechanisms 1 , accounting for the CF clinical phenotype 2 . CF morbidity and mortality are primarily caused by the associated lung disease, a consequence of mucus dehydration, reduced mucociliary clearance, recurrent infection and hyperinflammation of the airways 3 .
CFTR, a member of the ATP-binding cassette transporter superfamily, comprises two membrane-spanning domains (MSD1 and MSD2), two nucleotide-binding domains (NBD1 and NBD2) and a unique regulatory (R) domain 4 , which allosterically communicate at the functional and biochemical level [5] [6] [7] . The most common mutation, Δ F508 or F508del in NBD1, similar to numerous other missense mutations, impairs CFTR domain folding and folding cooperativity, rendering the channel susceptible to premature degradation within the ER, as well as after escaping the ER via the PM protein-quality-control mechanism 1, 8 . Targeted introduction of second-site suppressor mutations revealed that robust folding correction of Δ F508-CFTR requires stabilization of NBD1 and its interfaces with MSD2, established primary conformational defects of the Δ F508 mutant [9] [10] [11] or hyperstabilization of Δ F508-NBD1 (ref. 12 ). The intrinsic structural instability of mutant NBD1 that severely hampered the isolation of a hyperstabilizing corrector molecule for monotherapy 13 prompted us to resort to rationally designed combinatorial corrector therapy. This approach was also favored owing to the cooperative nature of domain folding of wild-type CFTR (WT-CFTR) and the cooperative misfolding of CF mutations (including Δ F508) distributed throughout the channel, manifesting in the propagation of localized misfolding to multiple domains [14] [15] [16] . As a consequence, we assumed that improving NBD1 folding and any permutation of domain-domain interactions should facilitate the conformational rescue of Δ F508-CFTR 16, 17 . This paradigm entails that the combination of correctors targeting both primary 9, 10 and secondary structural defects (e.g., NBD2 misfolding or its domain interactions 18 ) may more effectively restore biosynthetic processing of Δ F508-CFTR as well as other processing mutants than monotherapy 17 .
Mechanistically, type I correctors support the formation of NBD1-MSD1 and NBD1-MSD2 interfaces, type II correctors target NBD2 and/or its interfaces and type III correctors facilitate NBD1 folding and/or impede its unfolding 17 . We and others have shown that the combination of type I and type II correctors leads to modest correction of Δ F508-CFTR misfolding 17, [19] [20] [21] . Owing to the lack of available potent and effective type III correctors, chemical chaperones were used as surrogates in our proof-of-principle studies 17 . However, the clinical utility of chemical chaperones is very limited because of their modest potency and efficacy, as well as lack of specificity. VX-809 (lumacaftor) was until recently 22 the sole approved corrector 23 with a type I mechanism 17, 24 . VX-809 in combination with the gating potentiator VX-770 (ivacaftor) provides modest clinical benefit to 50% of patients with CF carrying two copies of the Δ F508 mutation 25 . The limited efficacy of VX-809-VX-770 combination (Orkambi) therapy may be attributed to the lack of Δ F508-NBD1 stabilization and the likely attenuated biogenesis of Δ F508-CFTR upon chronic VX-770 treatment 26, 27 . Thus, there is an unmet need to identify more efficacious correctors of Δ F508-CFTR folding defects that will translate into improved clinical benefit in patients with CF.
Here we report the isolation and characterization of novel type I, II and III corrector compounds that individually exhibit limited rescue of Δ F508-CFTR but in combination robustly restore the mutant biochemical and functional expression in airway cells. This triple corrector combination (3C) has profound rescue efficacy in primary human bronchial (HBE) and nasal epithelia (HNE) of Δ F508-homozygous patients and is also effective in a Δ F508 CF mouse model. Importantly, the 3C combination also rescued several CFTR2 (CFTR2 project: http://cftr2.org) 2 folding mutants with poor susceptibility to VX-809. The in vitro and in vivo results confirm the feasibility of the proposed framework for allosteric folding correction of various CFTR mutants and the efficacy of a structureguided selection strategy for corrector combinations.
Results
Identification of ΔF508-CFTR corrector hits with different scaffolds. To isolate corrector molecules targeting distinct structural defects of Δ F508-CFTR with limited efficacy, we selected our recently developed biochemical screening assay 19, 26 , which displays enhanced sensitivity for detection of CFTR at the PM relative to that of the halide-sensitive functional measurements ( Fig. 1a and Supplementary Fig. 1a -c). To this end, Δ F508-CFTR, containing a horseradish peroxidase isoenzyme C (HRP-C) in its fourth extracellular loop, was expressed in CFB41o-cells, an established human bronchial epithelial model with CFTR ΔF508/ΔF508 genetic background but no detectable CFTR expression 28 .
PM expression of the mutant was detected by luminometry in the presence of the cell-impermeant substrate 19, 26 in 1,536-well plates. We screened ~600,000 drug-like compounds in the ~250-550-Da molecular weight range from the Novartis academic collection screen (ACS) library with robust signal-to-background ratios and Z' factors, a measure of statistical effect size ( Fig. 1b ). Two primary screens were performed to preferentially select type II and type III corrector hits-one in the presence of VX-809 and another using a Δ F508-CFTR variant that contained the interface-stabilizing mutation p.R1070W 9, 17, 29 . These screens yielded 2,967 and 1,890 primary hits, respectively, of which 125 compounds were identified in both screens on the basis of the increase in luminescence signal by > 3 s.d. relative to DMSO or VX-809 treated controls ( Fig. 1b ). Dose-response measurements in the presence and absence of VX-809 confirmed 39 active compounds ( Fig. 1c -f, Supplementary  Fig. 1d ,e and Supplementary Table 1 ).
To determine whether PM accumulation of Δ F508-CFTR was correlated with its functional gain, the PM anion conductance was determined via the halide-sensitive yellow fluorescent protein (YFP) quenching assay ( Supplementary Fig. 1b ) 26 after PKA activation with forskolin, 3-isobutyl-1-methyl-xanthine (IBMX), 8-(4-chlorophenylthio)-adenosine-3′ ,5′ -cyclical monophosphate (cpt-cAMP) and potentiation of the channel with genistein. On the basis of the interaction and interdependence of hits with VX-809 and the relation between Δ F508-CFTR functional gain and PM density, we categorized the hits into four groups: group I promoted Δ F508-CFTR conductance only in absence of VX-809, group II increased the channel function in combination with VX-809, group III increased Δ F508-CFTR function regardless of the VX-809 presence, and group IV increased Δ F508-CFTR function by < 20% ( Fig. 1c and Supplementary Fig. 1f -h).
Within these groups we next identified clusters of compounds sharing a common scaffold: group I contained the 6258 series of sulfamoyl-pyrrol compounds (6258, 3170, 6224) ( Fig. 1d ), group II contained the 3151 series of aminothiazole compounds (3151, 3140, 3150, 3152 supplemented by 3149 and 3154 from group III and group IV, respectively) ( Fig. 1e ) and group III contained the 4172 series of pyrazole compounds (4172, 3158, 3159, supplemented by 2216, 3835 and 3836 from limited SAR screen) ( Fig. 1f ). The halfmaximal effective concentration (EC 50 ) of Δ F508-CFTR functional correction in CFBE41o-cells for the representative 6258, 3151 and 4172 compounds was 0.16, 4.2 and 3.1 µ M, respectively (Fig. 1d-f  and Supplementary Table 1 ).
Clustering corrector hits on the basis of mechanism of action.
First, we used surface plasmon resonance (SPR) as previously described 13 to test whether any of the best representative correctors could directly bind to isolated Δ F508-NBD1. The 4172 compound, but not 3151 or 6258, showed dose-dependent binding with an equilibrium dissociation constant (K D ) = 38 µ M to the in vivo biotinylated Δ F508-NBD1, containing the single stabilizing mutation p.F494N ( Fig. 2a, b , Supplementary Fig. 2a,b and Supplementary  Table 2 ), a necessary prerequisite for a type III mechanism of corrector action. We also confirmed that bromoindole-3-acetic acid (BIA), the first identified type III corrector 12 , has an affinity that is > 25-fold lower (K D > 1,000 µ M) 13 than that of 4172 ( Supplementary Fig. 2c,d and Supplementary Table 2 ).
Compound 6258 was able to promote Δ F508-CFTR accumulation at the PM only in the absence of VX-809. This was confirmed by the dose-dependent inhibitory effect of VX-809 ( Fig. 2c ). Vice versa, exposure of Δ F508-CFTR to 6258 reduced the VX-809induced PM expression of Δ F508-CFTR in CFBE41o-cells ( Fig. 2c ). We documented that, similarly to VX-809 (ref. 24 ), 6258 exposure corrected the PM density of several processing mutations in the MSD1 (E56K-, P67L-and L206W-CFTR to > 25% of WT; it also corrected E92K-CFTR to a lower extent) expressed in CFBE41ocells ( Fig. 2d ). VX-809 can stabilize the N-terminal fragments of WT-CFTR, encompassing amino acids (aa) 1-380 (refs 17, 24 ) that may resemble the mutant folding intermediates. Likewise, 6258 treatment induced the accumulation of the N-terminal CFTR fragments: aa 1-380 (MSD1), aa 1-653 (MSD1-Δ F-NBD1) and aa 1-837 (MSD1-Δ F-NBD1-R), but not aa 1-370, in CFBE41o-cells ( Fig. 2e ). Jointly, these results suggest that despite the divergent chemical structure, 6258 exhibits a type I mechanism of action and may have an overlapping binding site with VX-809.
The aminothiazol compound 3151 has structural similarity to the investigational type II correctors C4 and D-01 that require NBD2 for corrector action 17, 19, 30 . The folding efficacy of a subset of the initial 39 compounds, but not of VX-809, was reduced or prevented upon deletion of the NBD2 domain in a Δ F508-CFTR variant containing three solubilizing mutations (F494N, Q637R and F429S 31 ; Δ F508-3S-1218 × -CFTR) that partially restore NBD1 folding but not the NBD1-MSD2 interface defect ( Fig. 2f and Supplementary  Fig. 2e ). Concordantly, the presence of C4 alone or with VX-809 reduced the corrector efficacy of these compounds, suggesting an overlapping mechanism of action ( Fig. 2g and Supplementary Fig.  2f ,g). We infer that members of the 3151 series likely conform to a type II mechanism, as their efficacy was compromised by NBD2 deletion and C4 competition ( Fig. 2h ).
Cooperative rescue of biogenesis, PM expression and stability by corrector combinations.
We used combinatorial profiling of correctors with distinct mechanisms of action to optimize for additive or synergistic rescue of Δ F508-CFTR PM density and function. First, we tested pair-wise combinations of type I (6258 and VX-809), II (C4 and 3151), III [2-(5-bromo-1H-indol-1-yl) acetic acid (BIA29, a structural analog of BIA)] and putative type III (4172, 3158) correctors by comparing their efficacy with that of the calculated additivities of individual compounds ( Fig. 3a and Supplementary Fig. 3a,b ). As expected, combinations of mechanistically similar correctors (for example, BIA29 and 4172; 4172 and 3158; VX-809 and 6258; and C4 and 3151) failed to exert additive rescue or showed negative cooperativity, whereas combinations of different types elicited more than additive folding rescue ( Fig. 3a and Supplementary Fig. 3b ). This paradigm became more apparent when, after normalizing for the mRNA level ( Supplementary  Fig. 3c ), Δ F508-CFTR PM density and the abundance of the mature, complex-glycosylated form (band C) was expressed as percentage of WT-CFTR ( Fig. 3b-d ). Combination of the putative type III (4172) and type I (VX-809) correctors increased the Δ F508-CFTR PM density and band C to 76% and 47% of WT, respectively, in CFBE41o-cells ( Fig. 3b-d ). Remarkably, 3 C of 3151 (type II) with 4172 and VX-809 restored PM density and band C expression of Δ F508-CFTR to the WT level, translating into > 10-fold higher corrector efficacy than VX-809 treatment alone ( Fig. 3b-d ). Replacing VX-809 with type I corrector 6258 in the combination also elevated PM density and band C accumulation of Δ F508-CFTR to 65% and 85% of WT, respectively ( Fig. 3b-d) .
To test the specificity of the new correctors, we determined their effect on the PM density of other native or conformationally defective membrane proteins. Combinations of 4172, 6258 and 3151 alone or with VX-809 did not substantially affect the PM expression of the transferrin receptor (TfR) or the chimeric proteins HRP-CD4TM and HRP-CD4TM-λ WT (bacteriophage λ repressor fused to the transmembrane domain of CD4), as well as the mutant form HRP-CD4TM-λ L57C , representing native and misfolded endosomal or PM-targeted transmembrane model proteins 32 ( Supplementary Fig. 3d-f ). Likewise, treatment with either single correctors or 3C negligibly altered the PM density of mutants of polytopic transmembrane proteins, associated with inherited conformational diseases: megalencephalic leukoencephalopathy with subcortical cyst 1 (MLC1-P92S and MLC1-S280L) 33 , diabetes insipidus (vasopressin 2 receptor; V2R-Y128S) 32, 34 and Long QT2 syndrome (human Ether-à-go-go-Related Gene; hERG-G601S) 35 ( Supplementary Fig. 3g ,h).
The Δ F508 mutation diminishes the conformational maturation efficiency of CFTR at the ER from ~40% to < 1% and accelerates the channel turnover in post-ER compartments 1, 16 . To test whether corrector combinations can rectify these defects, first the folding efficiency of the Δ F508-CFTR nascent chains was measured via the metabolic pulse-chase technique. The conversion of the pulselabeled core-glycosylated channel into the complex-glycosylated form indicated that the maturation efficiency of WT-CFTR 14, 16 was Supplementary Table 4 .
reduced from ~41% to ~2.3% by the Δ F508 mutation in the presence of VX-809 (ref. 26 ) ( Fig. 3e ). Corrector combinations 4172 and VX-809; 4172, 6258 and 3151 or 4172, VX-809 and 3151, however, enhanced the ER folding efficiency of the mutant to 8%, 13%, and 25%, respectively ( Fig. 3e ). Thus, the mutant maximum folding efficiency reached ~60% of the WT in the presence of 3C, representing a > 10-fold increase of the VX-809 effect.
Corrector combinations also led to stabilization of the mature, complex-glycosylated Δ F508-CFTR, measured by immunoblotting and cycloheximide (CHX)-chase ( Fig. 3f,g) . The 3C rendered WT-like cellular stability in the mutant (Fig. 3f,g) . Similar results were obtained for Δ F508-CFTR stability at the PM (Fig. 3h ), indicating that the stability of both the PM and post-ER pools of rescued Δ F508-CFTR approached that of the WT. Thus, the combination of Supplementary Table 4 . The uncropped versions of the immunoblots in b and f and of the autoradiographs in e are shown in Supplementary Fig. 11 . different types of correctors profoundly increases both the biogenesis efficacy and post-ER stability of mature Δ F508-CFTR, likely by shifting its final fold to near-native conformation.
To support this inference, we determined the protease resistance of the complex-glycosylated mutant in microsomes, isolated from cells exposed to 3C for 24 h, via limited trypsinolysis and immunoblotting with domain-specific antibodies. The protease sensitivity of the full-length Δ F508-CFTR ( Fig. 4a ) as well as its domains (NBD2, MSD1 and MSD2) ( Supplementary Fig. 4 ) was dramatically higher than that of the WT, confirming the mutant global misfolding 15, 16, 36 .
Treatment with 3C profoundly increased the protease resistance of the mature Δ F508-CFTR and its individual domains close to that of its WT counterpart, suggesting that domain folding was allosterically propagated and effectively led to global conformational correction ( Fig. 4a and Supplementary Fig. 4 ).
Functional rescue of ΔF508-CFTR by corrector combinations.
Corrector-induced PM and band C accumulation of the Δ F508-CFTR correlated well with its functional recovery, measured by short-circuit current (I sc ), stimulated by forskolin and The WT-or Δ F508-CFTR conformation in isolated microsomes was probed by limited trypsinolysis and immunoblotting (left). Microsomes isolated from BHK-21 cells, treated with DMSO, VX-809 or 3C (4172+ VX-809+ 3151), were exposed to increasing concentrations of trypsin, and the remaining full-length CFTR was quantified by immunoblotting. Complexglycosylated WT-or Δ F508-CFTR was expressed as the percentage of the initial amount (right; n = 4). b, Correlation between the PM density (n = 3) and band C abundance (n = 5) or activation (Fsk + Gen, n = 3) of Δ F508-CFTR after treatment with single correctors or corrector combinations as determined in Fig. 3c,d and d , respectively. The Pearson correlation coefficient and the associated P value are shown. c,d, The effect of the indicated single correctors or corrector combinations on the short-circuit current (I sc ) of Δ F508-CFTR in CFBE41o-cells. Representative traces are shown in c. Δ F508-CFTR function (n = 3) normalized with CFTR RNA abundance ( Supplementary Fig. 3c ) is expressed as percentage of WT function in d, in which red, blue and green indicate single, double and triple corrector treatment, respectively. e,f, The effect of VX-809 or 3C on thermal inactivation of Δ F508-CFTR-2RK reconstituted into an artificial phospholipid bilayer. The P o of protein kinase A-activated CFTRs was analyzed at the indicated temperatures (e) for WT (total recording time for each point 16-23 min, n = 11-19, exact number of independent records for each temperature is indicated in the graph), Δ F508-2RK acute potentiation (Fig. 4b) . However, the functional gain was ~50% less than expected on the basis of the PM density measurements. I sc was 19% and 47% of the WT after exposing the cells to the 4172 plus VX-809 and 3C correctors, respectively (Fig. 4c, d and Supplementary Fig. 5a ). Addition of 3C during I sc measurement caused a small (~12%) but significant decrease in the maximal I sc of 3C-corrected Δ F508-CFTR ( Supplementary Fig. 5b) , an observation that led us to explore whether individual correctors can exhibit some inhibitory effect. Acute addition of 4172 and 3151 decreased the forskolin-stimulated I sc of low-temperature-rescued Δ F508-CFTR, both with and without potentiation ( Supplementary  Fig. 5c,d) and of WT-CFTR ( Supplementary Fig. 5e ). The inhibitory effect of 4172 and 3151 on Δ F508-CFTR was ~15% and ~25%, respectively ( Supplementary Fig. 5f )-this at least in part explains the attenuated functional correction efficacy.
The effect of corrector combination on single-molecule Δ F508-CFTR, containing the R29K and R555K (2RK) mutations, was measured after reconstitution of the temperature-rescued channel into the planar phospholipid bilayer 37 . These second site mutations increased the reconstitution efficiency without significantly influencing the Δ F508-CFTR functional and biochemical phenotype 17, 37, 38 . Thermal inactivation of the phosphorylated Δ F508-CFTR-2RK was demonstrated by the progressive reduction of the open probability (P o ) from 0.19 to 0.09 upon increasing the bilayer temperature from 24 to 36 °C 17,26 (Fig. 4e) . In contrast, the WT P o increased from 0.31 to 0.44 during the temperature ramp ( Fig. 4e ). Acute addition of VX-809 delayed the thermal inactivation of Δ F508-CFTR, resulting in a P o of 0.2 at 36 °C 17 . Addition of 3C reversed the mutant thermal inactivation and conferred increased activity at 36 °C (P o 0.45 ± 0.08, n = 11) similar to the WT (Fig. 4e,f and Supplementary Fig. 5g ). The mean closed time of Δ F508-CFTR-2RK in presence of 3C was reduced from ~700 ms to 65 ms at 36 °C, similar to that of the WT ( Supplementary Fig. 5h ), implying a near-normal opening kinetics. In contrast to a single open state of the WT, Δ F508-CFTR-2RK exhibited a bimodal distribution of its mean open time. The 3C increased the prevalence of the longer openings at 36 °C ( Supplementary Fig. 5h ). Taken together, these findings indicate that the 3C can confer thermal stability to the rescued Δ F508-CFTR functional conformation at 36 °C, which is similar, but not identical, to that of the WT.
Functional correction of human CFTR ΔF508/ΔF508 bronchial and nasal epithelia. To confirm the efficacy of corrector combinations in human tissue, CFTR function was monitored in primary HBE isolated from five individuals with CF homozygous for Δ F508 (CF-HBE) and from lungs from five donors without CF (WT-HBE) after differentiation at the air-liquid interface (ALI). We confirmed that VX-809 increased the forskolin-activated and potentiated I sc of Δ F508-CFTR from 6% to 27% relative to that of WT-CFTR (Fig. 5a,b and Supplementary Fig. 6a ), as reported 23, 26, 39 . The best double combination (4172 with VX-809) and 3C increased the Δ F508-CFTR I sc to 37% and 49% of the WT, respectively (Fig. 5a,b and Supplementary Fig. 6a,b) . Importantly, Δ F508-CFTR functional correction in CFBE41o-and CF-HBE cells was highly correlated, indicating the predictive capacity of the transduced CFBE41o-model for screening and mechanistic studies of CFTR modulators ( Supplementary Fig. 6d ). Corrector combinations also decreased the potentiator-dependent fraction of the forskolin-stimulated Δ F508-CFTR I sc (Fig. 5b, lower panel) . The forskolin-activated I sc increased from 9% to 16% and 20% of WT after correction with VX-809, 4172 + VX-809 and 3C treatment, respectively ( Supplementary Fig. 6c) .
A large interdonor variation in the maximally stimulated I sc was documented in CF-HBE cells from homozygous Δ F508-CFTR patients, as noted earlier 26, 39 . Considering that a recent publication established a tight correlation between corrector effect in the more easily accessible patient-derived human nasal epithelia (CF-HNE) cells and the clinical outcome of corrector therapy 40 , we isolated HNE from 17 individuals with CF homozygous for Δ F508 (CF-HNE) and five non-CF donors (WT-HNE). HNE were amplified through the conditional reprogramming (CR) technique 41, 42 and characterized 43 . Similar to CF-HBE, VX-809 and 3C increased the forskolin-activated and potentiated Δ F508-CFTR I sc in CF-HNE from 10% to 28% and 48%, respectively, of WT-CFTR (Fig. 5c,d and Supplementary Fig. 6e ). The relative rescue of I sc between CF-HBE and CF-HNE was strongly correlated, suggesting that HNE are a good surrogate model to measure CFTR function in CF individuals (Fig. 5e ). The Δ F508-CFTR function in HNE after 3C ranged between 20% and 85% of the WT, significantly higher than after VX-809 treatment alone (Fig. 5d ). For all individual homozygous Δ F508 CF-HNE, the channel function after 3C exceeded the I sc achieved by VX-809 exposure ( Supplementary Table 3 ). Similar to Δ F508-CFTR response in CF-HBE 26, 27 , chronic treatment of CF-HNE with the gating potentiator VX-770 decreased the VX-809 corrector efficacy (Fig. 5d ). This phenomenon was also observed in 3C-treated CF-HNE. However, the remaining Δ F508-CFTR function, 34% of the WT, would likely still surpass the threshold required for clinical benefit (Fig. 5d ).
Functional correction of ΔF508-CFTR in mice.
Although less severe than in humans, the Δ F508 mutation leads to a substantial folding defect of CFTR in mice 44 . To determine the functional Δ F508-CFTR correction capacity of 3C in vivo, the corrector combination was topically instilled into the noses of Δ F508 Cftr tm1EUR mice 45 . Although DMSO had no effect ( Supplementary Fig. 7a ), 3C exposure for 24 h significantly increased the chloride secretion, as determined by an increase in the low chloride and forskolinstimulated trans-epithelial potential difference (V t ) from -1.0 mV to -2.9 mV, which corresponds to ~35% of the WT level 46 in the absence of potentiator ( Fig. 5f-h) . The CFTR channel blocker CFTR inh -172 was able to inhibit the 3C-restored chloride secretion, suggesting CFTR specificity. This inference was substantiated by the lack of 3C effect on nasal potential difference (NPD) in the CFTRknockout mouse strain Cftr tm1Unc ( Supplementary Fig. 7b ). These results suggest that topical administration of the 3C combination, even without potentiator, results in substantial correction of the Δ F508-CFTR current in vivo.
Allosteric rescue of some CFTR2 mutants by triple-corrector combination.
Cooperative domain folding and propagation of primary conformational defects to all structured domains caused by certain missense mutations distributed throughout CFTR 15 raised the possibility of allosteric folding correction independent of the mutation location. To test this hypothesis, we determined the biochemical and functional rescue efficiency of 14 CF mutants that were confined to the four structured domains and were associated with CFTR folding and processing defects 1, 47 . The mRNA-normalized ( Supplementary Fig. 8a ) PM density of CFTR2 variants confirmed the varying severity of CFTR expression defects in CFBE41o-cells, similar to that reported in FRT 47 . Remarkably, the PM density of all but three CFTR2 mutants was significantly increased to > 25% of WT by 3C (Fig. 6a) . Independent of the mutation location, combination of VX-809 with the type II (3151) and putative type III (4172) correctors yielded the highest correction efficacy at the PM level ( Fig. 6a and Supplementary Fig. 8b ). Comparable effect was detected by measuring the accumulation of complex-glycosylated CFTR2s in post-ER compartments (Fig. 6b,c) .
Similar to Δ F508-CFTR, for some mutants, the fractional PM channel activity, defined as macroscopic function divided by CFTR PM density, did not reach the untreated WT level even after 3C and acute potentiator treatment ( Supplementary Fig. 9a,b) . Nevertheless, corrector combination increased the I sc (Fig. 6d ,e and Supplementary Table 4 . Supplementary Fig. 9a ) and the potentiator-independent forskolinactivated I sc fraction for most mutants ( Supplementary Fig. 9c ). These results suggest that patients carrying a variety of folding mutations could benefit from corrector combinations that simultaneously stabilize distinct domains and/or domain interfaces, resulting in improved cooperative domain folding. This conclusion is supported by the increased trypsin resistance of the L1077P-CFTR at the full-length channel and individual domain levels in microsomes, isolated from 3C-exposed cells ( Supplementary Fig. 10 ).
Discussion
Although significant research and drug development efforts 19, 23, 30, [48] [49] [50] have led to several clinical trials (Cystic fibrosis drug development pipeline: http://www.cff.org/trials/pipeline), until recently, the only approved corrector drug for treating patients with CF carrying two copies of the Δ F508 mutation was VX-809 (lumacaftor) in combination with the gating potentiator VX-770 (ivacaftor) 25 . VX-809, however, has only modest clinical benefit, considering that in combination with VX-770 (2.6-4% absolute gain of predicted FEV1%) 25 it can restore just ~25% of the WT-CFTR function in homozygous Δ F508 primary CF-HBE cells 23 . VX-661 (tezacaftor), which has a similar efficacy in CF-HBE cells 26 and in combination with VX-770, resulted in comparable gain in lung function in homozygous Δ F508 patients (4% absolute gain of predicted FEV1%) 22 and was approved in February 2018. Using biochemical screens in combination with VX-809 or a suppressor mutation (R1070W), here we identified novel, mechanistically distinct corrector compounds that target individual components of the complex structural defects of Δ F508-CFTR. Through rational selection of compounds targeting three kinds of conformational defects of Δ F508-CFTR, the 3C resulted in complete (103%) biochemical and ~48% functional restoration of Δ F508-CFTR relative to WT and in partial alleviation of the potentiator requirement. The conformational stability of the 3C-corrected NBD2, MSD1 and MSD2 and full-length Δ F508-CFTR, probed by . The domain localizations of the mutations are indicated. b,c Effect of VX-809 or 3C treatment on the expression pattern of CFTR2 mutants in CFBE41o-cells determined by immunoblot (b) and densitometric quantification (c; n = 6 for R31C, E92K, R347P, D614G, L1077P; n = 3 for P67L, L206W, S492F, V520F, S1235R). Uncropped immunoblots are presented in Supplementary  Fig. 11. d,e , Effect of VX-809 or 3C on the I sc of CFTR2 mutants in CFBE41o-cells. Representative traces are shown in d. Mutant function (n = 3), expressed as percentage of WT function, is depicted in e. Data in a, c and e were normalized to mutant CFTR2 mRNA abundance ( Supplementary Fig. 8a) and are means ± s.e.m. of the indicated number of independent experiments.
limited trypsinolysis, became comparable to that of the WT, suggesting that major conformational defects do not persist in the corrected Δ F508-CFTR. Meanwhile, the incomplete functional rescue by 3C suggests that pharmacological chaperone-assisted folding may trap Δ F508-CFTR in a stable but partially functional state and/ or that the macromolecular signaling complex of Δ F508-CFTR at the PM 51,52 is only partly assembled. In conjunction with the small inhibitory effect of some of the corrector molecules, this may explain the reduced fractional channel activity. Mechanistic clustering of hits identified compound 4172 as a putative type III corrector, with a binding affinity to isolated Δ F508-NBD1 of ~40 µ M and an EC 50 of ~3 µ M for functional increase of Δ F508-CFTR in epithelial cells. This increased in vivo potency of 4172 may be explained by the intracellular accumulation or enhanced affinity to the full-length CFTR. The most effective Δ F508-CFTR biochemical and functional correction was achieved when 4172 treatment was combined with type I (VX-809 or 6258) and type II (3151) correctors that act on NBD1-MSDs and NBD2, respectively. The 3151 corrector structurally resembles the previously described aminothiazol compounds, C4 and D-01 (refs 17, 19, 30 ). These results substantiate the prediction 9,10,17 that combining correctors targeting distinct structural defects can overcome their limited individual efficacies and robustly rescue the Δ F508-CFTR folding defect.
Although the precise binding sites of the identified correctors remain to be elucidated, functional stabilization of single Δ F508-CFTR channels similar to that of the WT in the phospholipid bilayer 38 suggests that these compounds act by directly binding to and promoting the refolding and/or native state stability of the mutant as pharmacological chaperones. The inability of 3C to rescue several conformationally defective PM proteins, although having significant rescue efficacy of Δ F508-CFTR in CFBE41o-cells, primary CF-HBE and CF-HNE and the NPD in Δ F508 Cftr tm1EUR mice, further supports the pharmacochaperone-like activity of 3C over an indirect effect via the perturbation of cellular proteostasis. The implication of the latter results is that the CFBE41o-model, which heterologously expresses tagged CFTR variants, has a predictive value and can serve as an authentic model for corrector selection for drug-resistant mutations.
The 3C also elicited near-complete biochemical correction of several rare CFTR folding mutants that displayed modest susceptibility to VX-809 and no clear correlation between the correction level and the mutation localization. The requirement of corrector interaction with multiple domains and interfaces of the mutant to achieve robust Δ F508-CFTR correction is also in line with the highly cooperative folding and misfolding processes of CFTR 14, 15 , which permit allosteric correction of the global conformation defect elicited by other missense CF mutations located in MSD1, MSD2, NBD1 or NBD2. On the basis of this observation, we predict other VX-809-resistant missense mutations may be susceptible to combinatorial corrector rescue as well.
To increase the correction efficacy of Δ F508-CFTR, several strategies were devised, including the identification and manipulation of modifier genes 39, [53] [54] [55] , as well as altering cellular proteostasis activity, including modulation of chaperone or autophagy activities [56] [57] [58] [59] . Our approach, to target distinct Δ F508-CFTR folding defects with combinations of pharmacological chaperones, was able to restore homozygous Δ F508-CFTR function to ~50% of the WT level, a value that is deemed sufficient to alleviate clinical manifestations in half of patients with CF, as heterozygous carriers lack disease symptoms 60 . Moreover, the achieved correction level would likely provide benefit to the 40% compound heterozygous patients with CF that carry the Δ F508 mutation in one allele and possibly to patients with CF with rare folding mutations with a nonresponsive (for example, premature termination codon) mutation on the second allele.
Online content
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Methods
Antibodies and reagents. Mouse monoclonal anti-hemagglutinin (HA) antibody was purchased from Covance (clone: 16B12, catalog no: MMS-101R, dilution 1:1,000). Monoclonal anti-CFTR antibody clone M3A7 (recognizing aa 1365-1395 at the C terminus of NBD2, catalog no: MAB3480, dilution 1:500) and clone MM13-4 mouse monoclonal anti-CFTR antibody (specific to the N-terminal 25-36 residues, catalog no: MAB3482, dilution 1:1,000) were from Millipore. The 660 anti-CFTR antibody recognizing NBD1 has been characterized previously 14 and was used at a dilution of 1:2,000. Monoclonal mouse anti-Na+ /K+ -ATPase (Santa Cruz Biotechnology, clone: H3, catalog no: sc-48345, dilution: 1:5,000) and monoclonal mouse anti-β -actin (Abcam, catalog no: ab8226, dilution: 1:2,000) were used as loading control. VX-770 and VX-809 were purchased from Selleckchem. For follow up studies, the small-molecule corrector compounds were acquired from Life Chemicals (4172 and 3151 series as well as BIA29) or Maybridge (6258 series), and their identities were confirmed by mass spectrometry. All other chemicals were purchased from Sigma-Aldrich at the highest grade available.
Cell lines. Full-length human WT-or Δ F508-CFTR with a 3HA tag or HRP tag in the fourth extracellular loop have been described 17, 26 . Nucleotide substitutions to generate other CFTR variants and second-site mutations were introduced by overlapping PCR mutagenesis, as described before 16 . The generation of CFBE41ocell lines expressing inducible CFTR variants has been described previously 61 .
CFBE41o-cells, provided by D. Gruenert, University of California, San Francisco (UCSF), San Francisco, CA, USA, were maintained in MEM (Invitrogen) supplemented with 10% FBS (Invitrogen), 2 mM l-glutamine and 10 mM HEPES. For experiments, the expression of CFTR variants was induced for ≥ 3 d with 500 ng/ml doxycycline.
Human bronchial and nasal epithelia. HBE cells isolated from the bronchi following lung transplantation of individuals with CF and without CF were a gift from W. Finkbeiner (UCSF) or were purchased from the Cystic Fibrosis Translational Research center (CFTRc) at McGill University. The isolation of HNE from healthy human subjects and those with CF was performed under the protocol and consent form approved by the McGill MUHC Research Ethics Board (14-234-BMB). All relevant ethical regulations were followed. Tissue collection and HNE cell isolation was performed as described 42 . Both HBE and HNE cells were conditionally reprogrammed 62 , followed by differentiation on Snapwell filter supports 63 .
Mouse strains. Congenic mice homozygous for the Δ F508 mutation, Δ F508 Cftr tm1EUR (FVB/N background) 64 Corresponding author(s): Guido Veit, Gergely L. Lukacs
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Experimental design 1. Sample size
Describe how sample size was determined.
Mouse study: The number of animals necessary was based on our previous case-control analysis derived from our population of 102 CFTRtm1Eur CF and 42 WT FVB control population. We used a multivariate discriminant analysis to develop a score to best discriminate between the CF and WT populations. This led us to determine that for a treatment effect of 40 % toward wild-type values, we needed at least 6 animals per group in a placebo control design to reach a power of 95% for an SD value of 0.1 (Faria da Cunha et al., Int J Biochem Cell Biol. 2016;80:87-97).
As the design of the study was slightly different, (e.g animals acting as their own control, reducing even more the variability of the measurement) we assumed that this number of 6 animals was sufficient, and increased it to 8 for more reliability.
Human respiratory epithelia: Our previous study (Veit et al., PLOS Biology 2016 14(5):e1002462) showed that HBE isolated from 5 individuals homozygous for ΔF508-CFTR are sufficient to significantly determine an effect corresponding to 25% of the WT-current. To encompass more of the naturally occurring variation in the residual ΔF508-CFTR current, we used HNE isolated from 17 individuals homozygous for ΔF508-CFTR.
Data exclusions
Describe any data exclusions.
No samples, mice or data points were excluded from the reported analyses.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
To verify reproducibility, CFTR modulator effects were recapitulated in cell models, primary human cells and animal models. Mutually supportive results were obtained in three independent laboratories, confirming reproducibility of the key findings of the study. All individual experiments were repeated for the number of times indicated in the manuscript. All the relevant data collected are included in the study and replication experiments were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was not applicable, since treatment/control were done in parallel (in vitro) on cells form the same individuals or sequentially (in vivo) in the same mice.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were not blinded, since no subjective analysis were performed. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used. Describe the software used to analyze the data in this study.
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Most study analysis were performed using Excel or GraphPad Prism. Dose-response fitting was performed with OriginPro 8, SPR data was analyzed with BIACORE T200 evaluation software, BLM recordings were analyzed with Clampfit 10.3, YFP quenching data was analyzed with XLfit 4.3. and immunoblot analysis were done using ImageJ 1.50i.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
All unique materials used in the study are readily available from the authors. Transduced CFBE cells are joint property of University California San Francisco and McGill University. The IP of the Clontech`s LentiX Tet-On Advanced System, used for transduction of the CFBR belongs to TET Systems GmbH & Co. KG, Germany.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). The CFBE41o-cells were generated by and are a kind gift from Dr. Dieter Gruenert (University of California, San Francisco). BHK-21 cells were purchased from ATCC. b. Describe the method of cell line authentication used. BHK-21 cells have been validated by ATCC and were obtained directly from ATCC. CFBE41owere directly received from Dr. Dieter Gruenert and have not been authenticated in our lab. c. Report whether the cell lines were tested for mycoplasma contamination.
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We routinely test cells for myocoplasma. All cells used in the study tested negative.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study. Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The isolation of human nasal epithelia (HNE) from healthy and subjects with CF was performed under the protocol and consent form approved by the McGill MUHC Research Ethics Board (14-234-BMB). The age/sex of the individuals homozygous for ΔF508-CFTR from which nasal tissue was obtained by scrape biopsy is listed in Supplementary Table 3 . The age range at the time of collection was 20-53 years (median 29) and the female:male ratio was 9:8.
